Research Article
Trends in Opioid Use in a Cohort of Patients with Rheumatoid Arthritis
Table 1
Sociodemographic characteristics and use of opioids by group in a cohort of 1,329 patients with rheumatoid arthritis in Colombia.
| | Variable | Total patients (n = 1329), number (%) | Opioids use patients (n = 1129), number (%) | Opioids use < 12 months (n = 601), number (%) | Opioids use ≥ 12 months (n = 528), number (%) |
| | Age (mean, (SD)) | 61.8 ± 12.1 | 61.2 ± 11.8 | 59.9 ± 12.3 | 62.6 ± 11.0 | | Age <45 years | 114 (8.6) | 107 (9.5) | 74 (12.3) | 33 (6.3) | | Age 45–64.9 years | 676 (50.9) | 602 (53.3) | 322 (53.6) | 280 (53.0) | | Age ≥ 65 years | 539 (40.5) | 420 (37.2) | 205 (34.1) | 215 (40.7) | | Female | 1103 (83.0) | 936 (82.9) | 495 (82.3) | 441 (83.5) | | Weak opioidsa | 1102 (82.9) | 1102 (97.6) | 584 (97.2) | 519 (98.3) | | Strong opioidsb | 167 (12.6) | 167 (14.8) | 60 (10.0) | 107 (20.3) |
|
|
aWeak opioids: codeine, dihydrocodeine, hydrocodone, tramadol, and tapentadol. bStrong opioids: fentanyl, morphine, oxycodone, hydromorphone, and methadone.
|
